|
|
|
| Significance of S100A6 Protein Expression in Thyroid Carcinoma |
| JIANG Yansong, ZHANG Bingxin, BAI Jiming, et al |
| Chengde Central Hospital, Hebei Chengde 067000, China |
|
|
|
|
Abstract Objective: To investigate the expression and clinical significance of S100A6 protein in thyroid carcinoma tissue, and to provide a favorable basis for clinical evaluation of the disease. Methods: One hundred and twenty patients with thyroid carcinoma admitted to our hospital from August 2016 to August 2021 were selected as the study group, and 120 patients with benign thyroid nodules in the same period were selected as the control group, and paraffin sections were taken for immunohistochemical staining to detect the expression level of S100A6 protein. Results: The positive rates of S100A6 protein expression were 12.50%, 81.25%, 30.00% and 13.46% in benign thyroid nodular, papillary thyroid carcinoma, medullary thyroid carcinoma and follicular carcinoma thyroid, respectively. As seen from Table 2, pairwise comparison showed that the positive rate of benign thyroid nodules and papillary thyroid carcinoma was statistically significant (P<0.05). The positive rate of benign thyroid nodules and medullary carcinoma was statistically significant (P<0.05). The comparison of the positive rate of benign thyroid nodules with follicular thyroid carcinoma was not statistically significant by statistical analysis (P>0.05). In contrast, the positive rate of papillary and medullary thyroid carcinoma compared with follicular thyroid carcinoma was statistically significant by statistical analysis (P<0.05). Conclusion: S100A6 protein is highly expressed in papillary thyroid carcinoma tissue, which can be used as an important biological indicator. At the same time, S100A6 protein can also be used as a predictor of thyroid carcinoma metastasis.
|
|
|
|
|
|
[1] Khan MA,Malik N,Ihan KH,et al.Association of preoperative serum thyroid-stimulating horm one levels with thyroid cancer in patients with nodular thyroid disease[J].World Jnucl Med,2017,16(3):202-205.
[2] 符丽茹.2096例甲状腺癌患者临床资料回顾性分析[D].唐山,华北理工大学,2021.
[3] 涂林雅.长沙市甲状腺术后患者智谋现状及其影响因素研究[D].湖南.湖南师范大学,2021.
[4] 米婧.CDC6、MCM7在甲状腺乳头状癌中的表达及临床意义[D].宁夏,宁夏医科大学,2021.
[5] Ito Y,Yoshida H,Tomoda C,et al.Expression of S100A2 and S100A6 in thyroid carcinomas[J].Histopathology,2005,46(5):569-575.
[6] Lim H,Devesa S S,Sosa J A,et al.Trends in thyroid cancer incidence and mortality in the United States,1974-2013[J].Jama,2017,317(13):1338-1348
[7] Xiangxiang Liu,Fan Yaguang,Liu Yuanchao,et al.The impact of radioactive iodine treatment on survival among papillary thyroid cancer patients according to the 7th and 8th editions of the AJCC/TNM staging system:a SEER-based study[J].Updates in Surgery,2020,72(3):871-884.
[8] Shunichi Yamashita,Suzuki Shinichi,Suzuki Satoru,et al.Lessons from fukushima:latest findings of thyroid cancer after the fukushima nuclear power plant accident[J].Thyroid:official journal of the American Thyroid Association,2018,28(1):11-22.
[9] 李鹏,梁跃东,刘建西,等.基于数据挖掘分析S100A6在肝细胞癌中的表达及临床意义[J].现代肿瘤医学,2020,28(12):2089-2094. |
|
|
|
2023, Vol. 29 
